

# Stephane Gibaud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8901508/publications.pdf>

Version: 2024-02-01

33  
papers

762  
citations

566801

15  
h-index

525886

27  
g-index

37  
all docs

37  
docs citations

37  
times ranked

999  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticancer properties of lipid and poly( $\epsilon$ -caprolactone) nanocapsules loaded with ferrocenyl-tamoxifen derivatives. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1474-1484.	1.2	8
2	Spray-dried microparticles of glutathione and S-nitrosoglutathione based on Eudragit <sup>®</sup> FS 30D polymer. <i>Annales Pharmaceutiques Francaises</i> , 2017, 75, 95-104.	0.4	12
3	The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 536-541.	1.0	2
4	Thiomers and their potential applications in drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 601-610.	2.4	21
5	Synthesis of S-nitrosoglutathione-alginate for prolonged delivery of nitric oxide in intestines. <i>Drug Delivery</i> , 2016, 23, 2927-2935.	2.5	16
6	Synthesis and characterization of S-nitrosoglutathione-oligosaccharide-chitosan as a nitric oxide donor. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1209-1223.	2.4	8
7	Phthalimido-ferrocenyl cyclodextrin complexes: Characterization and anticancer activity. <i>International Journal of Pharmaceutics</i> , 2015, 491, 323-334.	2.6	14
8	Effect of intravenous hydration in patients receiving bisphosphonate therapy. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 1277-1281.	1.0	3
9	Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?. <i>Annales Pharmaceutiques Francaises</i> , 2014, 72, 146-151.	0.4	0
10	Characterization of mitotane (o,p-DDD)-cyclodextrin inclusion complexes: Phase-solubility method and NMR. <i>Annales Pharmaceutiques Francaises</i> , 2013, 71, 186-192.	0.4	5
11	The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 560-568.	2.0	6
12	Microemulsions for oral administration and their therapeutic applications. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 937-951.	2.4	61
13	Place du mitotane dans la prise en charge du carcinome corticosurrénalien. <i>Actualites Pharmaceutiques Hospitalieres</i> , 2011, 7, 39-41.	0.1	1
14	Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1308.	1.3	51
15	Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1295-1301.	1.2	6
16	Development of microemulsion of mitotane for improvement of oral bioavailability. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 421-427.	0.9	38
17	Speciation of arsenic in urine following intravenous administration of arsthinol in mice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2010, 35, 59-65.	0.6	2
18	Arsenic-Based Drugs: From Fowler's Solution to Modern Anticancer Chemotherapy. <i>Topics in Organometallic Chemistry</i> , 2010, , 1-20.	0.7	40

#	ARTICLE	IF	CITATIONS
19	Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 1295-1301.	1.2	2
20	Comparison of nanosuspensions and hydroxypropyl- $\beta$ -cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 649-656.	2.0	47
21	Pharmacokinetics and tissue distribution of the antileukaemic organoarsenicals arsthinol and melarsoprol in mice. <i>Journal of Organometallic Chemistry</i> , 2007, 692, 1348-1352.	0.8	7
22	(2-Phenyl-[1,3,2]dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. <i>Journal of Organometallic Chemistry</i> , 2006, 691, 1081-1084.	0.8	21
23	Cyclodextrin Inclusion Complexes of the Central Analgesic Drug Nefopam. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 1123-1134.	0.9	15
24	Melarsoprol-cyclodextrins inclusion complexes. <i>International Journal of Pharmaceutics</i> , 2005, 306, 107-121.	2.6	61
25	Poly( $\mu$ -caprolactone) and Eudragit <sup>®</sup> microparticles containing fludrocortisone acetate. <i>International Journal of Pharmaceutics</i> , 2004, 269, 491-508.	2.6	29
26	Slow-release melarsoprol microparticles. <i>International Journal of Pharmaceutics</i> , 2002, 243, 161-166.	2.6	17
27	Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods. <i>International Journal of Pharmaceutics</i> , 2002, 242, 197-201.	2.6	7
28	Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). <i>Journal of Controlled Release</i> , 1998, 52, 131-139.	4.8	54
29	Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin- and doxorubicin-loaded nanoparticles. <i>International Journal of Pharmaceutics</i> , 1998, 166, 117-120.	2.6	10
30	Splenic trapping of nanoparticles: complementary approaches for in situ studies. <i>Pharmaceutical Research</i> , 1997, 14, 463-468.	1.7	47
31	Cells Involved in the Capture of Nanoparticles in Hematopoietic Organs. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 944-950.	1.6	56
32	Increased bone marrow toxicity of doxorubicin bound to nanoparticles. <i>European Journal of Cancer</i> , 1994, 30, 820-826.	1.3	79
33	Detection of bacterial adenosine triphosphate through bioluminescence, applied to a rapid sterility test of injectable preparations. <i>Analytica Chimica Acta</i> , 1991, 255, 423-425.	2.6	3